The collaboration establishes a framework to explore a multi-year, multi-study research program spanning cellular health, clinical evidence generation and commercial translation.
Longevity Life Sciences and the University of Sydney have established a strategic framework to explore a multi-year clinical research collaboration focused on the development and validation of interventions relevant to cellular health and healthy ageing.
The relationship is underpinned by a Memorandum of Understanding executed in July 2026, following earlier research and confidentiality agreements between the parties.
The proposed collaboration is designed as an evolving, multi-study research program, with an initial focus on CellVive NMN® and the potential to expand over time across additional cellular health compounds, clinical endpoints, biomarker research and translational work.
An initial clinical program involving CellVive NMN® is currently being developed. The parties are discussing a randomised, double-blind, placebo-controlled clinical study examining the effect of NMN supplementation in healthy adults.
Any individual clinical study will proceed subject to appropriate project-specific agreements, research governance, ethics approval and other relevant requirements.
The broader collaboration is intended to extend beyond a single study.
The parties intend to explore sequential and parallel clinical research, biomarker investigation and translational work capable of building a scalable clinical evidence base across the CellVive® platform.
Under the proposed research model, the University of Sydney would act as the lead academic institution for agreed studies, with responsibility for study design, protocol development and scientific conduct in accordance with recognised ethical and regulatory standards. The University would retain full academic independence in study conduct, data analysis and publication.
LLS would fund agreed research programs on a project-by-project basis, supply investigational products where applicable and support strategic direction, program prioritisation and commercial translation.
Associate Professor Sophie Stocker is the University’s nominated scientific contact for the collaboration.
For Longevity Life Sciences, the relationship represents an important evolution in the CellVive® model: extending beyond the regulatory and commercial translation of emerging science towards helping generate the high-quality clinical evidence that can inform its future.
